Please provide your email address to receive an email when new articles are posted on . High dose early mobilization is not recommended for those with diabetes in the ICU. A larger proportion of ...
Imagine standing up, taking your first step without pain, and feeling nearly as confident as you did decades earlier — all ...
INDIANAPOLIS (WISH) — Brian Stockman, the clinical director at Team Rehabilitation Facility in Broad Ripple, is helping patients recover from surgeries like total knee replacements through ...
The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient ...
A drug developed at Case Western at Case Western Biotechnology Incubator is showing promise in helping paralyzed patients ...
- Proof-of-concept study is initial step toward goal of identifying more efficient CD34+ HSC mobilization regimen for patients with sickle cell disease choosing gene therapy - TEL AVIV, Israel, Dec.
Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor We conducted a ...
Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461 Thirteen patients (MM, n = 7; NHL, n = 6) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results